CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
We are very excited to launch our new website! Please take a few moments to click around and explore...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...